These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
298 related items for PubMed ID: 9387863
1. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Morissette M, Goulet M, Soghomonian JJ, Blanchet PJ, Calon F, Bédard PJ, Di Paolo T. Brain Res Mol Brain Res; 1997 Oct 03; 49(1-2):55-62. PubMed ID: 9387863 [Abstract] [Full Text] [Related]
2. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. Morissette M, Grondin R, Goulet M, Bédard PJ, Di Paolo T. J Neurochem; 1999 Feb 03; 72(2):682-92. PubMed ID: 9930741 [Abstract] [Full Text] [Related]
3. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis. Goulet M, Morissette M, Calon F, Blanchet PJ, Falardeau P, Bédard PJ, Di Paolo T. Neuroscience; 1997 Jul 03; 79(2):497-507. PubMed ID: 9200732 [Abstract] [Full Text] [Related]
4. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex. Calon F, Goulet M, Blanchet PJ, Martel JC, Piercey MF, Bédard PJ, Di Paolo T. Brain Res; 1995 May 22; 680(1-2):43-52. PubMed ID: 7663983 [Abstract] [Full Text] [Related]
5. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine. Morissette M, Goulet M, Calon F, Falardeau P, Blanchet PJ, Bédard PJ, Di Paolo T. Mol Pharmacol; 1996 Nov 22; 50(5):1073-9. PubMed ID: 8913337 [Abstract] [Full Text] [Related]
6. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Herrero MT, Augood SJ, Hirsch EC, Javoy-Agid F, Luquin MR, Agid Y, Obeso JA, Emson PC. Neuroscience; 1995 Oct 22; 68(4):1189-98. PubMed ID: 8544992 [Abstract] [Full Text] [Related]
7. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Henry B, Crossman AR, Brotchie JM. Exp Neurol; 1999 Feb 22; 155(2):204-20. PubMed ID: 10072296 [Abstract] [Full Text] [Related]
8. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T. Synapse; 2006 Sep 01; 60(3):239-50. PubMed ID: 16739115 [Abstract] [Full Text] [Related]
9. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides. Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T. Neuropharmacology; 2010 Jan 01; 58(1):286-96. PubMed ID: 19576910 [Abstract] [Full Text] [Related]
10. Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys. Herrero MT, Augood SJ, Asensi H, Hirsch EC, Agid Y, Obeso JA, Emson PC. Brain Res Mol Brain Res; 1996 Nov 01; 42(1):149-55. PubMed ID: 8915594 [Abstract] [Full Text] [Related]
11. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Rioux L, Frohna PA, Joyce JN, Schneider JS. Mov Disord; 1997 Mar 01; 12(2):148-58. PubMed ID: 9087972 [Abstract] [Full Text] [Related]
12. Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions. Pirker W, Tedroff J, Pontén H, Gunne L, Andrén PE, Hurd YL. Exp Neurol; 2001 May 01; 169(1):122-34. PubMed ID: 11312565 [Abstract] [Full Text] [Related]
13. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys. Goulet M, Grondin R, Blanchet PJ, Bédard PJ, Di Paolo T. Brain Res; 1996 May 06; 719(1-2):129-37. PubMed ID: 8782872 [Abstract] [Full Text] [Related]
16. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T. Mov Disord; 2006 Jan 06; 21(1):9-17. PubMed ID: 16127720 [Abstract] [Full Text] [Related]
17. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Zeng BY, Pearce RK, MacKenzie GM, Jenner P. Eur J Neurosci; 2000 Mar 06; 12(3):1096-104. PubMed ID: 10762340 [Abstract] [Full Text] [Related]
18. Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. Ouattara B, Gasparini F, Morissette M, Grégoire L, Samadi P, Gomez-Mancilla B, Di Paolo T. J Neurochem; 2010 May 06; 113(3):715-24. PubMed ID: 20132464 [Abstract] [Full Text] [Related]